POS0052 ANGIOGENIC T CELLS AS RELEVANT PLAYERS IN THE LUNG VASCULOPATHY OF RHEUMATOID ARTHRITIS, SYSTEMIC SCLEROSIS AND OTHER AUTOIMMUNE DISEASES

Background Interstitial lung disease (ILD) is a common and life-threatening complication in patients with autoimmune diseases (AD), mainly those systemic sclerosis (SSc) rheumatoid arthritis (RA). Growing evidence indicate that vascular abnormalities constitute the early phase pathogenesis of these inflammatory [1]. We recently reported decrease angiogenic T cells (TAng), promote endothelial repair revascularization cooperating progenitor (EPC) [2], AD-ILD + [3]. Nevertheless, no studies have been conducted on role TAng presence ILD RA, SSc or other AD. Objectives To determine contribution pathogenic processes vasculopathy fibrosis RA-ILD , SSc-ILD as well their relationship EPC all patients. Methods Peripheral venous blood was collected from 21 patients, 15 . Furthermore, we included 4 comparative groups: 25 - 20 idiopathic pulmonary (IPF) healthy controls (HC). were considered CD3 CD184 CD31 by flow cytometry. Additionally, data previously published Pulito-Cueto et al. [4-5]. Results Regarding vasculopathy, frequencies significantly lower IPF relation to HC (p=0.007, p=0.016, p=0.005 p<0,001, respectively, Figure 1). No differences between found (Figure With respect involvement fibrosis, similar showed than respectively (p=0.006 p=0.044, In this line, higher frequency (p<0.001 p=0.003, Moreover, did not show significant correlation whole cohort 1. Quantification population cytometry individuals study. Conclusion play relevant Interestingly, circulating may be useful biomarker RA SSc. References [1]Expert Rev Clin Immunol 2018;14(1):69-82. [2]Rheum Dis 2015;74(5):921–927. [3]Ann Rheum 2021;80(1):1047-1048. [4]J Med 2020;9(12):4098. [5]Biomedicines 2021;9(7):847. Acknowledgements VP-C supported pre-doctoral grant IDIVAL (PREVAL18/01); SR-M funds RETICS Program (RD16/0012/0009) `Instituto de Salud Carlos III´ (ISCIII), co-funded European Regional Development Fund; RL-M recipient Miguel Servet type I programme fellowship ISCIII, Social Fund, `Investing your future’(grant CP16/00033). Disclosure Interests Verónica Pulito-Cueto: None declared, Sara Remuzgo-Martínez: Fernanda Genre: Belén Atienza-Mateo: Virginia Portilla: Victor Manuel Mora-Cuesta: David Iturbe Fernández: Leticia Lera-Gómez: Javier Rodriguez Carrio: Diana Prieto-Peña: Ricardo Blanco Speakers bureau: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen MSD, Consultant of: Grant/research support from: MSD Alfonso Corrales: Oreste Gualillo: Jose Cifrián-Martínez: Raquel López-Mejías: A González-Gay Sanofi, Lilly, Celgene, GSK, Janssen, Roche